<code id='969D87FB46'></code><style id='969D87FB46'></style>
    • <acronym id='969D87FB46'></acronym>
      <center id='969D87FB46'><center id='969D87FB46'><tfoot id='969D87FB46'></tfoot></center><abbr id='969D87FB46'><dir id='969D87FB46'><tfoot id='969D87FB46'></tfoot><noframes id='969D87FB46'>

    • <optgroup id='969D87FB46'><strike id='969D87FB46'><sup id='969D87FB46'></sup></strike><code id='969D87FB46'></code></optgroup>
        1. <b id='969D87FB46'><label id='969D87FB46'><select id='969D87FB46'><dt id='969D87FB46'><span id='969D87FB46'></span></dt></select></label></b><u id='969D87FB46'></u>
          <i id='969D87FB46'><strike id='969D87FB46'><tt id='969D87FB46'><pre id='969D87FB46'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:entertainment    Page View:64137
          Vertex Pharmaceuticals - sunset
          Bill Sikes/AP

          Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

          The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

          advertisement

          While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In